AI
BIO icon

Atria Investments’s Bio-Rad Laboratories Class A BIO Stock Holding History

Atria Investments’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$843K Sell
2,872
-1,162
-29% -$330K 0.01% 1207
2026
Q1 		$1.12M Buy
4,034
+659
+20% +$190K 0.01% 994
2025
Q4 		$1.02M Buy
3,375
+439
+15% +$137K 0.01% 1048
2025
Q3 		$823K Sell
2,936
-259
-8% -$70.5K 0.01% 1151
2025
Q2 		$771K Buy
3,195
+1,248
+64% +$295K 0.01% 1182
2025
Q1 		$474K Sell
1,947
-628
-24% -$189K 0.01% 1386
2024
Q4 		$846K Sell
2,575
-70
-3% -$23.8K 0.01% 1065
2024
Q3 		$885K Buy
2,645
+223
+9% +$70.8K 0.01% 1030
2024
Q2 		$661K Buy
+2,422
New +$704K 0.01% 1163
2020
Q2 		– Sell
-1,158
Closed -$406K – 555
2020
Q1 		$406K Buy
1,158
+247
+27% +$90.8K 0.03% 391
2019
Q4 		$337K Buy
+911
New +$321K 0.01% 936
2018
Q4 		– Sell
-1,077
Closed -$337K – 886
2018
Q3 		$337K Buy
+1,077
New +$334K 0.01% 730

Other funds holding BIO

First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Atria Investments's BIO Position: Q2 2026 in Review

Atria Investments reduced its Bio-Rad Laboratories Class A (BIO) stake by 29% in Q2 2026, selling an estimated $330K and leaving 2,872 shares worth $843K. The position accounts for 0.01% of the portfolio, ranked #1207.

Atria Investments first reported a position in BIO in Q3 2018 and has held it in 12 quarters since. The position peaked at $1.12M in Q1 2026. 400 funds tracked by Wall St. Rank hold BIO as of Q2 2026.

  • Atria Investments held 2,872 shares of Bio-Rad Laboratories Class A worth $843K as of Q2 2026.
  • Atria Investments sold 1,162 Bio-Rad Laboratories Class A shares in Q2 2026, an estimated $330K.
  • Bio-Rad Laboratories Class A made up 0.01% of Atria Investments's portfolio in Q2 2026, its #1207 holding.
  • Atria Investments first reported a position in Bio-Rad Laboratories Class A in Q3 2018 and has held it in 12 quarters since.
  • Atria Investments's Bio-Rad Laboratories Class A position peaked at $1.12M in Q1 2026.
  • 400 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2026.

Based on Atria Investments's 13F filing for Q2 2026, filed 28 Jul 2026.